In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The price of Cytek BioSciences Inc (NASDAQ: CTKB) closed at $3.55 in the last session, down -1.39% from day before closing price of $3.6. In other words, the price has decreased by -$1.39 from its previous closing price. On the day, 1.38 million shares were traded. CTKB stock price reached its highest trading level at $3.69 during the session, while it also had its lowest trading level at $3.46.
Ratios:
We take a closer look at CTKB’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.69 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 25.71. For the most recent quarter (mrq), Quick Ratio is recorded 4.95 and its Current Ratio is at 5.62. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.05.
On January 31, 2025, Goldman Downgraded its rating to Sell which previously was Buy and also lowered its target price recommendation from $7 to $4.50.
On December 14, 2023, Stephens started tracking the stock assigning a Overweight rating and target price of $9.Stephens initiated its Overweight rating on December 14, 2023, with a $9 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 02 ’25 when McCombe William D. bought 35,000 shares for $2.78 per share. The transaction valued at 97,300 led to the insider holds 55,746 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTKB now has a Market Capitalization of 449639456 and an Enterprise Value of 199924144. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.28 while its Price-to-Book (P/B) ratio in mrq is 1.19. Its current Enterprise Value per Revenue stands at 1.015 whereas that against EBITDA is -10.008.
Stock Price History:
The Beta on a monthly basis for CTKB is 1.35, which has changed by -0.44617784 over the last 52 weeks, in comparison to a change of 0.16821623 over the same period for the S&P500. Over the past 52 weeks, CTKB has reached a high of $7.63, while it has fallen to a 52-week low of $2.37. The 50-Day Moving Average of the stock is 10.32%, while the 200-Day Moving Average is calculated to be -24.06%.
Shares Statistics:
According to the various share statistics, CTKB traded on average about 1.20M shares per day over the past 3-months and 901630 shares per day over the past 10 days. A total of 127.60M shares are outstanding, with a floating share count of 114.61M. Insiders hold about 9.52% of the company’s shares, while institutions hold 59.63% stake in the company. Shares short for CTKB as of 1752537600 were 5648731 with a Short Ratio of 4.71, compared to 1749772800 on 5088272. Therefore, it implies a Short% of Shares Outstanding of 5648731 and a Short% of Float of 5.81.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The performance of Cytek BioSciences Inc (CTKB) in the stock market is under the watchful eye of 2.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is $0.02, with high estimates of $0.03 and low estimates of $0.01.
Analysts are recommending an EPS of between $0.04 and -$0.05 for the fiscal current year, implying an average EPS of -$0.0. EPS for the following year is $0.07, with 2.0 analysts recommending between $0.13 and $0.01.
Revenue Estimates
According to 4 analysts, the current quarter’s revenue is expected to be $46.35M. It ranges from a high estimate of $47.5M to a low estimate of $45.58M. As of the current estimate, Cytek BioSciences Inc’s year-ago sales were $46.62MFor the next quarter, 4 analysts are estimating revenue of $52.1M. There is a high estimate of $52.46M for the next quarter, whereas the lowest estimate is $51.8M.
A total of 5 analysts have provided revenue estimates for CTKB’s current fiscal year. The highest revenue estimate was $199.6M, while the lowest revenue estimate was $196M, resulting in an average revenue estimate of $197.94M. In the same quarter a year ago, actual revenue was $200.45MBased on 5 analysts’ estimates, the company’s revenue will be $213.57M in the next fiscal year. The high estimate is $222.98M and the low estimate is $200.7M.
